Synta Melanoma Data Coming in May
Luke Timmerman2/2/09
Synta, the Lexington, MA-based developer of cancer drugs, said today it has completed enrolling 630 patients in a clinical trial of its lead product candidate for melanoma that has spread through the body. The company (NASDAQ: SNTA) has a goal of releasing results from the study in May. We profiled Synta’s efforts to develop this drug, elesclomol, last month.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
Childhood Beach Vacations May Boost Melanoma Risk - U.S. News & World Report | OncoBlog.com
2/3/09 7:55 pm
[...] Synta Melanoma Data Coming in May (xconomy.com) [...]
Synta Melanoma Data Coming in May | Xconomy | Cancer and You Network
2/6/09 8:25 am
[...] See the rest here: Synta Melanoma Data Coming in May | Xconomy [...]